Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkin’s lymphoma

References

• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390.
   PubMed Web of Science ®Google Scholar
• Kraus M, Alimzhanov MB, Rajewsky N, et al. Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer. Cell. 2004;117(6):787–800. Epub 2004/ 06/10
   PubMed Web of Science ®Google Scholar
• Tolar P, Sohn HW, Pierce SK. The initiation of antigen-induced B cell antigen receptor signaling viewed in living cells by fluorescence resonance energy transfer. Nat Immunol. 2005;6(11):1168–1176. Epub 2005/ 10/04
   PubMed Web of Science ®Google Scholar
• Kuppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer. 2005;5(4):251–262.
   PubMed Web of Science ®Google Scholar
• Chen L, Widhopf G, Huynh L, et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 2002;100(13):4609–4614. Epub 2002/ 10/24
   PubMed Web of Science ®Google Scholar
• Herve M, Xu K, Ng YS, et al. Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity. J Clin Invest. 2005;115(6):1636–1643. Epub 2005/ 05/20
   PubMed Web of Science ®Google Scholar
• Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94(6):1848–1854. Epub 1999/ 09/09.
   PubMed Web of Science ®Google Scholar
• Davis RE, Ngo VN, Lenz G, et al. Chronic active B cell receptor signaling in diffuse large B cell lymphoma. Nature. 2010;463(7277):88–92.
   PubMed Web of Science ®Google Scholar
• Marcucci F, Mele A. Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities. Blood. 2011;117(6):1792–1798. Epub 2010/ 10/21
   PubMed Web of Science ®Google Scholar
• Sachen KL, Strohman MJ, Singletary J, et al. Self-antigen recognition by follicular lymphoma B-cell receptors. Blood. 2012;120(20):4182–4190. Epub 2012/ 10/02.
   PubMed Web of Science ®Google Scholar
• Burger JA, Tedeschi A, Barr PM, et al.Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia.N Engl J Med.2015;373.
   PubMed Web of Science ®Google Scholar
• Furman RR, Barrientos JC, Wagner-Johnston ND, et al. Idelalisib, a selective inhibitor of PI3Kδ, In combination with Bendamustine, Fludarabine Or Chlorambucil in patients with relapsed or refractory (R/R) Chronic Lymphocytic Leukemia (CLL). Blood. 2013;122(21):2878.
   Web of Science ®Google Scholar
• Byrd JC, Furman RR, Coutre SE, et al.Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.N Engl J Med.2013;369.
   Web of Science ®Google Scholar
• Farooqui MZH, Valdez J, Martyr S, et al. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol. 2015;16(2):169–176
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Schnaiter A, Paschka P, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood. 2014;123(21):3247–3254.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235–242.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7(5):379–391.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9(2):105–116.
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clinical Oncology: Official Journal Am Soc Clin Oncol. 2010;28(27):4184–4190.
   PubMed Web of Science ®Google Scholar
• Kahl BS, Hong F, Williams ME, et al. Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402. J Clinical Oncology: Official Journal Am Soc Clin Oncol. 2014;32(28):3096–3102.
   PubMed Web of Science ®Google Scholar
• Ardeshna KM, Qian W, Smith P, et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol. 2014;15(4):424–435.
   PubMed Web of Science ®Google Scholar
• Flinn IW, Van Der Jagt R, Kahl BS, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014;123(19):2944–2952. Epub 2014/ 03/05.
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203–1210.
   PubMed Web of Science ®Google Scholar
• Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012;367(6):520–531.
   PubMed Web of Science ®Google Scholar
• Hermine O, Hoster E, Walewski J, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. The Lancet. 2016;388(10044):565–575
   PubMed Web of Science ®Google Scholar
• Wilson WH, Young RM, Schmitz R, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21(8):922–926. Epub 2015/ 07/21.
   PubMed Web of Science ®Google Scholar
• Gopal AK, Kahl BS, De Vos S, et al. PI3Kδ inhibition by Idelalisib in patients with relapsed indolent lymphoma. New England J Med. 2014;370(11):1008–1018.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Morschhauser F, Bouabdallah K, et al. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Ann Oncol. 2017;28(9):2169–2178. Epub 2017/ 06/22.
   PubMed Web of Science ®Google Scholar
• RR F, Cheng S, Lu P, et al. Ibrutinib resistance in chronic lymphocytic leukemia. New England J Med. 2014;370(24):2352–2354.
   PubMed Web of Science ®Google Scholar
• Mocsai A, Zhou M, Meng F, et al. Syk is required for integrin signaling in neutrophils. Immunity. 2002;16(4): 547–558. Epub 2002/ 04/24.
   PubMed Web of Science ®Google Scholar
• Clements JL, Lee JR, Gross B, et al. Fetal hemorrhage and platelet dysfunction in SLP-76–deficient mice. J Clin Investig. 1999;103(1):19–25.
   PubMed Web of Science ®Google Scholar
• Rinaldi A, Kwee I, Taborelli M, et al. Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. Br J Haematol. 2006;132(3):303–316. Epub 2006/ 01/18.
   PubMed Web of Science ®Google Scholar
• Chen L, Monti S, Juszczynski P, et al. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood. 2008;111(4):2230–2237. Epub 2007/ 11/17
   PubMed Web of Science ®Google Scholar
• Sasaki T, J I-S, Jones RG, et al. Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration. Science (New York, NY). 2000;287(5455):1040–1046. Epub 2000/ 02/11
   Google Scholar
• Nienaber JJ, Tachibana H, Naga Prasad SV, et al. Inhibition of receptor-localized PI3K preserves cardiac β-adrenergic receptor function and ameliorates pressure overload heart failure. J Clin Investig. 2003;112(7):1067–1079.
   PubMed Web of Science ®Google Scholar
• Chang JD, Sukhova GK, Libby P, et al. Deletion of the phosphoinositide 3-kinase p110gamma gene attenuates murine atherosclerosis. Proc Natl Acad Sci U S A. 2007;104(19):8077–8082. Epub 2007/ 05/08
   PubMed Web of Science ®Google Scholar
• Durand CA, Hartvigsen K, Fogelstrand L, et al. Phosphoinositide 3-kinase p110 delta regulates natural antibody production, marginal zone and B-1 B cell function, and autoantibody responses. J Immunol. 2009;183(9):5673–5684. Epub 2009/ 10/22.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Kaufmann SH. Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies. Curr Treat Options Oncol. 2006;7(4): 285–294. Epub 2006/ 08/19.
   PubMedGoogle Scholar
• De Weers M, Verschuren MC, Kraakman ME, et al. The Bruton’s tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages. Eur J Immunol. 1993;23(12):3109–3114. Epub 1993/ 12/01
   PubMed Web of Science ®Google Scholar
• Vetrie D, Vorechovsky I, Sideras P, et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature. 1993;361(6409):226–233. Epub 1993/ 01/21
   PubMed Web of Science ®Google Scholar
• Mahajan S, Ghosh S, Sudbeck EA, et al. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton’s tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide]. J Biol Chem. 1999;274(14):9587–9599. Epub 1999/ 03/27
   PubMed Web of Science ®Google Scholar
• Cinar M, Hamedani F, Mo Z, et al. Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis. Leuk Res. 2013;37(10):1271–1277. Epub 2013/ 08/22
   PubMed Web of Science ®Google Scholar
• Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010;107(29):13075–13080. Epub 2010/ 07/10
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Sharman J, J S, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010;115(13):2578–2585. Epub 2009/ 12/08. .
   PubMed Web of Science ®Google Scholar
• Flinn IW, Bartlett NL, Blum KA, et al. A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Eur J Cancer. 1990;2016(54):11–17. Epub 2015/ 12/29
   Google Scholar
• Sharman J, Hawkins M, Kolibaba K, et al. An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2015;125(15):2336–2343. Epub 2015/ 02/20
   PubMed Web of Science ®Google Scholar
• Sharman JP, Kolibaba KS, Shustov AR, et al. Results of a phase 2 trial evaluating efficacy and safety of Entospletinib (GS-9973) in patients with mantle cell lymphoma. Blood. 2016;128(22):2963.
   Google Scholar
• Lannutti BJ, Meadows SA, Herman SE, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood. 2011;117(2):591–594. Epub 2010/ 10/21
   PubMed Web of Science ®Google Scholar
• Flinn IW, Kahl BS, Leonard JP, et al. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-delta, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood. 2014;123(22):3406–3413. Epub 2014/ 03/13.
   PubMed Web of Science ®Google Scholar
• Miller BW, Przepiorka D, De Claro RA, et al. FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma. Clin Cancer Res: an Official Journal of the American Association for Cancer Research. 2015;21(7):1525–1529. Epub 2015/ 02/04
   PubMed Web of Science ®Google Scholar
• Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National Lymphocare Study. J Clinical Oncology: Official Journal Am Soc Clin Oncol. 2015;33(23):2516–2522. Epub 2015/ 07/01.
   PubMed Web of Science ®Google Scholar
• Gopal AK, Kahl BS, Flowers CR, et al. Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy. Blood. 2017;129(22):3037–3039. Epub 2017/ 03/23.
   PubMed Web of Science ®Google Scholar
• Coutre S, Leonard J, Flowers C, et al. Idelalisib monotherapy and durable responses in patients with relapsed or refractory Waldenstroms Macroglobulinemia (WM). J Clin Oncol. 2015;33(15_suppl):8532.
   Web of Science ®Google Scholar
• Kahl BS, Spurgeon SE, Furman RR, et al. A phase 1 study of the PI3Kdelta inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). Blood. 2014;123(22):3398–3405. Epub 2014/ 03/13
   PubMed Web of Science ®Google Scholar
• Brown JR, Byrd JC, Coutre SE, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014;123(22):3390–3397. Epub 2014/ 03/13
   PubMed Web of Science ®Google Scholar
• Iyengar S, Clear A, Bodor C, et al. P110alpha-mediated constitutive PI3K signaling limits the efficacy of p110delta-selective inhibition in mantle cell lymphoma, particularly with multiple relapse. Blood. 2013;121(12):2274–2284. Epub 2013/ 01/24
   PubMed Web of Science ®Google Scholar
• Liu N, Rowley BR, Bull CO, et al. BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110alpha and p110delta activities in tumor cell lines and xenograft models. Mol Cancer Ther. 2013;12(11):2319–2330. Epub 2013/ 10/31
   PubMed Web of Science ®Google Scholar
• Patnaik A, Appleman LJ, Tolcher AW, et al. First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin’s lymphomas. Ann Oncol. 2016;27(10):1928–1940.
   PubMed Web of Science ®Google Scholar
• Winkler DG, Faia KL, DiNitto JP, et al. PI3K-delta and PI3K-gamma inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol. 2013;20(11):1364–1374. Epub 2013/ 11/12
   PubMed Web of Science ®Google Scholar
• Flinn IW, Miller CB, Ardeshna KM, et al. Dynamo: a phase 2 study demonstrating the clinical activity of duvelisib in patients with relapsed refractory indolent non-hodgkin lymphoma. Blood. 2016;128(22):1218.
   Web of Science ®Google Scholar
• Flinn I, Oki Y, Patel M, et al. a phase 1 evaluation of duvelisib (ipi-145), a Pi3k-δ,γ inhibitor, in patients with relapsed/refractory iNHL. Blood. 2014;124(21):802.
   Web of Science ®Google Scholar
• Casulo C, Sancho J-M, Van Eygen K, et al. Contempo: preliminary results in first-line treatment of follicular lymphoma with the oral dual PI3K-δ,γ Inhibitor, Duvelisib, in combination with Rituximab or Obinutuzumab. Blood. 2016;128(22):2979.
   Web of Science ®Google Scholar
• Deng C, Lipstein MR, Scotto L, et al. Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies. Blood. 2017;129(1):88–99.
   PubMed Web of Science ®Google Scholar
• Mahadevan D, Pauli EK, Cutter K, et al. A phase I trial of TGR-1202, a next generation once daily PI3K-Delta inhibitor in combination with Obinutuzumab plus chlorambucil, in patients with chronic lymphocytic leukemia. Blood. 2015;126(23):2942.
   Web of Science ®Google Scholar
• Nastoupil LJ, Lunning MA, Vose J, et al. Tolerability and activity of chemo-free triplet combination of TGR-1202, ublituximab, and ibrutinib in patients with advanced CLL and NHL. J Clin Oncol. 2017;35(15_suppl):7511.
   Google Scholar
• Forero-Torres A, Ramchandren R, Yacoub A, et al. Results from a phase 1/2 study of INCB050465, a highly selective and highly potent PI3Kδ Inhibitor, in patients with relapsed or refractory B-cell malignancies (CITADEL-101). Blood. 2017;130(Suppl 1):410.
   PubMedGoogle Scholar
• Niemann CU, Mora-Jensen HI, Dadashian EL, et al. Combined BTK and PI3Kdelta Inhibition with Acalabrutinib and ACP-319 improves survival and tumor control in CLL Mouse Model. Clin Cancer Res: an Official Journal of the American Association for Cancer Research. 2017;23(19):5814–5823. Epub 2017/ 06/25.
   PubMed Web of Science ®Google Scholar
• Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clinical Oncology: Official Journal Am Soc Clin Oncol. 2013;31(1):88–94. Epub 2012/ 10/10.
   PubMed Web of Science ®Google Scholar
• Wang ML, Rule S, Martin P, et al. Targeting BTK with Ibrutinib in relapsed or refractory mantle-cell lymphoma. New England J Med. 2013;369(6):507–516.
   PubMed Web of Science ®Google Scholar
• Dubovsky JA, Beckwith KA, Natarajan G, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013;122(15):2539–2549.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Jurczak W, Jerkeman M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. The Lancet. 2016;387(10020):770–778
   PubMed Web of Science ®Google Scholar
• Gonzalez D, Martinez P, Wade R, et al. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. J Clinical Oncology: Official Journal Am Soc Clin Oncol. 2011;29(16):2223–2229. Epub 2011/ 04/13.
   PubMed Web of Science ®Google Scholar
• Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenström’s Macroglobulinemia. New England J Med. 2012;367(9):826–833.
   PubMed Web of Science ®Google Scholar
• Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenström’s Macroglobulinemia. New England J Med. 2015;372(15):1430–1440.
   PubMed Web of Science ®Google Scholar
• Noy A, De Vos S, Thieblemont C, et al. Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. Blood. 2017;129(16):2224–2232.
   PubMed Web of Science ®Google Scholar
• Bartlett NL, LaPlant BR, Qi J, et al. Ibrutinib monotherapy in relapsed/refractory Follicular Lymphoma (FL): preliminary results of a phase 2 Consortium (P2C) Trial. Blood. 2014;124(21):800.
   Web of Science ®Google Scholar
• Young RM, Staudt LM. Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov. 2013;12(3):229–243. Epub 2013/ 03/02
   PubMed Web of Science ®Google Scholar
• Wu J, Zhang M, Acalabrutinib LD. (ACP-196): a selective second-generation BTK inhibitor. J Hematol Oncol. 2016;9(1):21.
   PubMedGoogle Scholar
• Byrd JC, Harrington B, O’Brien S, et al. (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374.
   Web of Science ®Google Scholar
• Wang M, Rule S, Zinzani PL, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. The Lancet. 2017;391(10121):659–667.
   PubMed Web of Science ®Google Scholar
• Tam C, Grigg AP, Opat S, et al. The BTK Inhibitor, Bgb-3111, Is safe, tolerable, and highly active in patients with relapsed/refractory B-Cell Malignancies: initial report of a phase 1 first-in-human trial. Blood. 2015;126(23):832.
   Google Scholar
• Zhu J, Li J, Zhou J, et al. BGB-3111, a highly specific BTK inhibitor, is well tolerated and highly active in Chinese patients with relapsed/refractory B-Cell Malignancies: initial report of a phase 1 trial in China. Blood. 2017;130(Suppl 1):5347.
   Google Scholar
• Wu J, Zhang M, Liu D. Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside. Oncotarget. 2017;8(4):7201–7207.
   PubMedGoogle Scholar
• Burke RT, Meadows S, Loriaux MM, et al. A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor. Oncotarget. 2014;5(4):908–915. Epub 2014/ 03/25
   PubMedGoogle Scholar
• Barr PM, Saylors GB, Spurgeon SE, et al. Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL. Blood. 2016;127(20):2411–2415.
   PubMed Web of Science ®Google Scholar
• Wang ML, Lee H, Chuang H, et al. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncol. 2016;17(1):48–56. Epub 2015/ 12/08.
   PubMed Web of Science ®Google Scholar
• Jain N, Thompson PA, Ferrajoli A, et al. Combined Venetoclax and Ibrutinib for patients with previously untreated high-risk CLL, and relapsed/refractory CLL: a phase II trial. Blood. 2017;130(Suppl 1):429.
   Google Scholar
• Gill S, Frey NV, Hexner EO, et al. CD19 CAR-T cells combined with ibrutinib to induce complete remission in CLL. J Clin Oncol. 2017;35(15_suppl):7509.
   Google Scholar
• Ujjani CS, Jung S-H, Pitcher B, et al. Phase I trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: alliance A051103. Blood. 2016.
   Google Scholar
• Smith SM, Pitcher B, Jung S-H, et al. Unexpected and serious toxicity observed with combined Idelalisib, Lenalidomide and Rituximab in relapsed/refractory B cell lymphomas: alliance A051201 and A051202. Blood. 2014;124(21):3091.
   Web of Science ®Google Scholar
• Maruyama D, Nagai H, Fukuhara N, et al. Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma. Cancer Sci. 2016;107(12):1785–1790. Epub 2016/ 09/13
   PubMed Web of Science ®Google Scholar
• Coutre SE, Barrientos JC, Brown JR, et al. Management of adverse events associated with idelalisib treatment: expert panel opinion. Leuk Lymphoma. 2015;56(10):2779–2786. Epub 2015/ 03/03
   PubMed Web of Science ®Google Scholar
• Shanafelt TD, Borah BJ, Finnes HD, et al. Impact of Ibrutinib and Idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels. J Oncol Pract. 2015;11(3):252–258.
   PubMed Web of Science ®Google Scholar
• Mohanty AR, Sandoval N, Das M, et al. CCND1 mutations increase protein stability and promote Ibrutinib resistance in mantle cell lymphoma. Blood. 2016;128(22):4094.
   Web of Science ®Google Scholar
• MFM DR, Kuil A, Kater AP, et al. Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy. Blood. 2015;125(14):2306–2309.
   PubMed Web of Science ®Google Scholar
• Bashash D, Safaroghli-Azar A, Dadashi M, et al. Anti-tumor activity of PI3K-delta inhibitor in hematologic malignant cells: shedding new light on resistance to Idelalisib. Int J Biochem Cell Biol. 2017;85: 149–158. Epub 2017/ 03/04.
   PubMed Web of Science ®Google Scholar
• Yahiaoui A, Meadows SA, Sorensen RA, et al. PI3Kdelta inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kdelta and BTK inhibitors. PloS One. 2017;12(2):e0171221. Epub 2017/ 02/09
   PubMed Web of Science ®Google Scholar
• Pula A, Stawiski K, Braun M, et al. Efficacy and safety of B-cell receptor signaling pathway inhibitors in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis of randomized clinical trials. Leuk Lymphoma. 2018;59(5):1084–1094. Epub 2017/ 09/12.
   PubMed Web of Science ®Google Scholar